Januvia and Alimta drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Januvia (sitagliptin phosphate) and Alimta (pemetrexed disodium). Common drug interactions include peritonitis among females and attention deficit/hyperactivity disorder among males.

The phase IV clinical study analyzes what interactions people have when they take Januvia and Alimta. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Januvia?

Januvia has active ingredients of sitagliptin phosphate. It is often used in diabetes. eHealthMe is studying from 72,818 Januvia users. Check the latest studies of Januvia.

What is Alimta?

Alimta has active ingredients of pemetrexed disodium. eHealthMe is studying from 7,702 Alimta users. Check the latest studies of Alimta.

On Jul, 09, 2026

16 people who take Januvia and Alimta together, and have interactions are studied.

What are the common drug interactions of Januvia and Alimta, by gender? *:

female:

Peritonitis (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs)
Skin hyperpigmentation (disorders affect the colour of your skin)
Tongue discolouration (colour change of tongue)

male:

Attention deficit/hyperactivity disorder
Disturbance in attention
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Renal tubular necrosis (death of kidney tubules)
Upper gastrointestinal haemorrhage (upper gastrointestinal bleeding)
Abasia (inability to walk)
Acute respiratory failure
Asthenia (weakness)
Constipation
Death

What are the common drug interactions of Januvia and Alimta, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Interstitial lung disease
Neoplasm progression (growth of tumour)

60+:

Attention deficit/hyperactivity disorder
Disturbance in attention
Renal tubular necrosis (death of kidney tubules)
Upper gastrointestinal haemorrhage (upper gastrointestinal bleeding)
Abasia (inability to walk)
Acute respiratory failure
Asthenia (weakness)
Constipation
Death
Decreased appetite

What are the existing conditions these people have? *

Constipation: 6 people, 37.50%
Lung Neoplasm Malignant (cancer tumour of lung): 5 people, 31.25%
Urination - Excessive Volume: 2 people, 12.50%
Lung Adenocarcinoma Stage Iv (the cancer has spread to other organs of the body, such as the other lung, brain, or liver): 2 people, 12.50%
Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs): 2 people, 12.50%
Liver Disorder (liver diseases): 2 people, 12.50%
Type 2 Diabetes: 2 people, 12.50%
Lung Adenocarcinoma Metastatic (a form of non-small cell lung cancer spreads to other part): 2 people, 12.50%
Lung Adenocarcinoma Stage Iii (the cancer has spread to nearby tissue or too far away lymph nodes): 2 people, 12.50%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 2 people, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Januvia and Alimta?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously